A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol
To determine the effect of ezetimibe and simvastatin given together, and ezetimibe and simvastatin given alone on intestinal cholesterol absorption...
Brief Summary
Official Title: “A Randomized, Double-Blind, Placebo-Controlled,4-Period, Crossover Study to Evaluate the Effects of Ezetimibe and Simvastatin, Coadministered and Alone, on Intestinal Absorption of Cholesterol”
To determine the effect of ezetimibe and simvastatin given together, and ezetimibe and simvastatin given alone on intestinal cholesterol absorption.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic
- Study Primary Completion Date: April 2004
Detailed Clinical Trial Description
Patients will be randomized into 1 of 4 treatment sequences involving 4 consecutive 7-week treatment periods.
Intervention(s) in this Clinical Trial
- Drug: ezetimibe
- ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
- Drug: Comparator: Placebo (unspecified)
- matching placebo tablet. Duration of Treatment 31 Weeks.
- Drug: simvastatin
- simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
- Active Comparator: 2
- ezetimibe 10 mg tablet
- Active Comparator: 3
- simvastatin 20 mg tablet
- Placebo Comparator: 4
- matching placebo
Outcome Measures for this Clinical Trial
Primary Measures
- reduced intestinal cholesterol absorption with ezetimibe + simvastatin vs simvastatin alone.
- Time Frame: Based on 7 week treatment periods.
Safety Issue?: No
- Time Frame: Based on 7 week treatment periods.
Secondary Measures
- To determine the effects of ezetimibe alone and simvastatin alone on intestinal cholesterol absorption.
- Time Frame: Based on 7 week treatment periods.
Safety Issue?: No
- Time Frame: Based on 7 week treatment periods.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Healthy males between the ages of 18-55 with LDL More than 130, but less than 180
Exclusion Criteria:
- Individuals with drug or substance abuse
- Individuals with poor mental function
- Individuals having more than 14 alcoholic drinks a week
- Individuals that have been treated with any other investigational drug in the last 30 days
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 55 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Merck Industry
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Merck
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00652301
Study ID Number: 2007_559
ClinicalTrials.gov Identifier: NCT00652301
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
MedWatch - FDA maintained medical product safety Information
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00652301
